Video Programs

Daniel O. Persky, MD, reflects on a patient’s relapse with diffuse large B-cell lymphoma and the rationale behind treatment with polatuzumab + BR.

A review of frontline treatment options for DLBCL informed by comprehensive patient workup and the efficacy of available therapies.

Expert hematologist/oncologist Daniel O. Persky, MD, reviews the case of a 73-year-old woman who is diagnosed with and treated for DLBCL, later to relapse and require novel therapy.

Joel Neal, MD, PhD, and Alexander I Spira, MD, PhD, FACP, review amivantamab and poziotinib as other treatment options for EGFR Exon 20 Insertion+ NSCLC.

An explanation of the EXCLAIM Trial and the mechanism of action, clinical development, and the overall clinical development program of mobocertinib.

Dr Evan Y. Yu shares sequencing strategies for LuPSMA radioligand therapy in patients with PSMA-positive mCRPC.

Evan Y. Yu, MD, reviews the phase 2 TheraP trial evaluating PSA response in patients with PSMA-positive mCRPC who received LuPSMA therapy vs cabazitaxel.

Dr Evan Y. Yu reviews the use of 177Lu-PSMA-617 therapy in patients with progressive PSMA-positive mCRPC as seen in the phase 3 VISION trial.

Evan Y. Yu, MD, shares insight on the rationale for precision medicine in patients with progressive PSMA-positive metastatic castration resistant prostate cancer (mCRPC) who have been previously treated with androgen axis inhibitor drugs and taxane.

Joel Neal, MD, PhD, and Alexander I Spira, MD, PhD, FACP, review current treatments for EGFR Exon 20 Insertion+ NSCLC, their preferred treatments, and current clinical trials.

Experts review the demographics of patients who should be tested and how to discuss EGFR Exon 20 Insertion+ NSCLC with patients.

A discussion on how this variant of NSCLC differs from the (exon 19 and exon 21) EGFR mutations and the demographics of EGFR patients.

Joel Neal, MD, PhD, and Alexander I Spira, MD, PhD, FACP, discuss the recent identification of EGFR exon 20 insertion+ mNSCLC and how patients responded before the new drugs were introduced.

Dr Perry Cook discusses the challenges of treating relapsed/refractory follicular lymphoma in later lines and describes ongoing developments in the treatment landscape.

A hematologist/oncologist provides insights on individualizing second-line therapy for patients with relapsed/refractory follicular lymphoma.

Perry Cook, MD, reviews the role of molecular testing and biomarkers in treatment selection in patients with follicular lymphoma.

A hematologist/oncologist discusses the tazemetostat as a treatment option for patients with relapsed/refractory follicular lymphoma.

A key opinion leader explains the first-line treatment options for follicular lymphoma and the challenges of treating patients with early disease progression.

Perry Cook, MD, presents the case of a 76-year-old man with relapsed/refractory follicular lymphoma.

Laurie Sehn, MD, discusses the unmet needs and future directions in the treatment of relapsed/refractory diffuse large B-cell lymphoma.

A key opinion leader reviews novel therapies for diffuse large B-cell lymphoma.

Dr Laurie Sehn reviews the NCCN guidelines for second-line therapy in relapsed/refractory diffuse large B-cell lymphoma and discusses the clinical trial data for a recently approved new treatment combination.

An expert hematologist-oncologist describes risk assessment for diffuse large B-cell lymphoma, as well as first-line therapy selection based on risk and other factors.

Laurie Sehn, MD, presents the case of a 76-year-old man with relapsed/refractory diffuse large B-cell lymphoma.

Dr Yi-Bin Chen shares his thoughts on future directions and unmet needs in treatment of steroid-refractory GVHD.

Key opinion leader, Yi-Bin Chen, MD, summarizes the clinical trial data supporting the recent FDA approval of ruxolitinib for the treatment of steroid-refractory acute GVHD and provides insights on a potential future role for ruxolitinib in steroid-refractory chronic GVHD.

Dr Yi-Bin Chen reviews treatment options for patients with steroid-refractory chronic GVHD.

Yi-Bin Chen, MD, discusses several approaches to the treatment of steroid-refractory acute GVHD, along with the immunologic pathways they target.

An expert in bone marrow transplantation outlines the main therapy used in the front-line setting to treat GVHD and then provides several definitions of what it means to be steroid-refractory.

Dr Yi-Bin Chen describes several prophylactic regimens commonly used to prevent GVHD following allogeneic hematopoietic stem cell transplant.